This article is more than 5 years old. Information may no longer be current.
Renflexis, a biosimilar to Remicade, launched in the US
Click Here to Manage Email Alerts
Renflexis, a biosimilar for Remicade that was approved by the FDA in April, has now been launched in the United States, according to a company press release.
“Since we were established 5 years ago, we have strived to bring high-quality treatment options at a lower cost to U.S. patients,” Christopher Hansung Ko, president and chief executive officer of Samsung Bioepis, Co., Ltd., said in the release. “We firmly believe biosimilars will play an instrumental role in making health care more accessible to patients across the U.S., and we will continue our relentless drive to advance one of the industry’s strongest pipelines.”
Renflexis (infliximab-abda, Samsung and Merck) — the third biosimilar to launch in the United States — will have a wholesale acquisition cost of $753, which is a 35% discount compared to Remicade’s (infliximab, Janssen) wholesale cost, according to the release; however, wholesale costs do not include discounts.
Reference: